SVRA
Savara Inc
NASDAQ · Healthcare · Biotechnology · US
$4.63
+4.04%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -22.7%
- EBIT
- -22.3%
- EPS
- -13.7%
- Free cash flow
- -11.3%
- Operating cash flow
- -11.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +3.8%
- EPS
- +8.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -16.1%
- EBIT
- -19.7%
- Net income
- -23.9%
- EPS
- -10.4%
- Free cash flow
- -13.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026